I lyset af ovenstående bør blodtranfusion i nogle kliniske situationer være den foretrukne behandling af anæmi hos patienter med cancer.
erythropoietins should be based on a benefit-risk assessment with the participation of the individual patient, which should take into account the specific clinical context.